eISSN: 2081-2841
ISSN: 1689-832X
Journal of Contemporary Brachytherapy
Current Issue Archive Supplements Articles in Press Journal Information Aims and Scope Editorial Office Editorial Board Register as Author Register as Reviewer Instructions for Authors Abstracting and indexing Subscription Advertising Information Links
SCImago Journal & Country Rank

Interview with Professor Janusz Skowronek
ABS 2015
vol. 10
Original paper

Image-guided interstitial high-dose-rate brachytherapy in the treatment of metastatic esophageal squamous cell carcinoma

Jazan Omari, Constanze Heinze, Antje Wilck, Peter Hass, Max Seidensticker, Robert Damm, Katharina Fischbach, Jens Ricke, Maciej Pech, Maciej Powerski

J Contemp Brachytherapy 2018; 10, 5: 439–445
Online publish date: 2018/10/23
View full text
Get citation
JabRef, Mendeley
Papers, Reference Manager, RefWorks, Zotero
To evaluate the efficacy of computed tomography (CT)- and magnetic resonance imaging (MRI)-guided interstitial high-dose-rate brachytherapy (HDR IBT = IBT) in patients with metastatic esophageal squamous cell carcinoma.

Material and methods
Eleven patients with 21 unresectable metastases of histologically proven esophageal squamous cell carcinoma were included in this retrospective study. Fourteen visceral and 7 lung metastases were treated with image-guided (CT or open MRI guidance) IBT using a 192Iridium source (single fraction irradiation). Clinical and imaging follow-up were performed every 3 months after treatment. Primary endpoint was local tumor control (LTC) and safety. Furthermore, we analyzed safety, progression-free survival (PFS), and overall survival (OS).

The median diameter of the target lesions was 2.2 cm (range: 0.7-6.8 cm), treated with a median D100 of 20.1 Gy (range: 10-25 Gy). During a median follow-up of 6.3 months (range: 3-21.8 months), three patients displayed local recurrences, resulting in LTC of 85.7%. Median PFS was 3.4 months and median OS after IBT was 13.7 months. No severe adverse events (grade 3+) requiring hospitalization or invasive intervention were recorded.

Image-guided IBT is a safe and effective treatment in patients with metastasized esophageal squamous cell carcinoma.


esophageal cancer, image-guided intervention, interventional oncology, interstitial brachytherapy, metastases

Ferlay J, Soerjomataram I, Dikshit R et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136: 359-386.
Jain S, Dhingra S. Pathology of esophageal cancer and Barrett’s esophagus. Ann Cardiothorac Surg 2017; 6: 99-109.
Van Rossum PSN, Mohammad NH, Vleggaar FP et al. Treatment for unresectable or metastatic oesophageal cancer: current evidence and trends. Nat Rev Gastroenterol Hepatol 2018; 15: 235-249.
Nakagawa S, Kanda T, Kosugi S et al. Recurrence pattern of squamous cell carcinoma of the thoracic esophagus after extended radical esophagectomy with three-field lymphadenectomy. J Am Coll Surg 2004; 198: 205-211.
Mariette C, Balon JM, Piessen G et al. Pattern of recurrence following complete resection of esophageal carcinoma and factors predictive of recurrent disease. Cancer 2003; 97: 1616-1623.
Hulscher JB, van Sandick JW, Tijssen JG et al. The recurrence pattern of esophageal carcinoma after transhiatal resection. J Am Coll Surg 2000; 191: 143-148.
Kunisaki C, Makino H, Takagawa R et al. Surgical outcomes in esophageal cancer patients with tumor recurrence after curative esophagectomy. J Gastrointest Surg 2008; 12: 802-810.
Abate E, DeMeester SR, Zehetner J et al. Recurrence after esophagectomy for adenocarcinoma: defining optimal follow-up intervals and testing. J Am Coll Surg 2010; 210: 428-435.
Dresner SM, Griffin SM. Pattern of recurrence following radical oesophagectomy with two-field lymphadenectomy. Br J Surg 2000; 87: 1426-1433.
Blom RL, Lagarde SM, van Oudenaarde K et al. Survival after recurrent esophageal carcinoma has not improved over the past 18 years. Ann Surg Oncol 2013; 20: 2693-2698.
Lordick F, Mariette C, Haustermans K et al. Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016; 27: v50-v57.
Weichselbaum RR, Hellman S. Oligometastases revisited. Nat Rev Clin Oncol 2011; 8: 378-382.
Aigner F, Pratschke J, Schmelzle M. Oligometastatic disease in colorectal cancer – how to proceed. Visc Med 2017; 33: 23-28.
Bretschneider T, Mohnike K, Hass P et al. Efficacy and safety of image-guided interstitial single fraction high-dose-rate brachytherapy in the management of metastatic malignant melanoma. J Contemp Brachytherapy 2015; 7: 154-160.
Collettini F, Lutter A, Schnapauff D et al. Unresectable colorectal liver metastases: percutaneous ablation using CT-guided high-dose-rate brachytherapy (CT-HDBRT). Rofo 2014; 186: 606-612.
Geisel D, Denecke T, Collettini F et al. Treatment of hepatic metastases from gastric or gastroesophageal adenocarcinoma with computed tomography-guided high-dose-rate brachytherapy (CT-HDRBT). Anticancer Res 2012; 32: 5453-5458.
Ricke J, Wust P, Stohlmann A et al. CT-guided interstitial brachytherapy of liver malignancies alone or in combination with thermal ablation: phase I-II results of a novel technique. Int J Radiat Oncol Biol Phys 2004; 58: 1496-1505.
Bretschneider T, Ricke J, Gebauer B, Streitparth F. Image-guided high-dose-rate brachytherapy of malignancies in various inner organs - technique, indications, and perspectives. J Contemp Brachytherapy 2016; 8: 251-261.
Parry K, Visser E, van Rossum PS et al. Prognosis and treatment after diagnosis of recurrent esophageal carcinoma following esophagectomy with curative intent. Ann Surg Oncol 2015; 22 (Suppl 3): S1292-1300.
Dutton SJ, Ferry DR, Blazeby JM et al. Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial. Lancet Oncol 2014; 15: 894-904.
Garden OJ, Rees M, Poston GJ et al. Guidelines for resection of colorectal cancer liver metastases. Gut 2006; 55: iii1-iii8.
Nguyen KT, Laurent A, Dagher I et al. Minimally invasive liver resection for metastatic colorectal cancer: a multi-institutional, international report of safety, feasibility, and early outcomes. Ann Surg 2009; 250: 842-848.
Huddy JR, Thomas RL, Worthington TR, Karanjia ND. Liver metastases from esophageal carcinoma: is there a role for surgical resection? Dis Esophagus 2015; 28: 483-487.
Van Daele E, Scuderi V, Pape E et al. Long-term survival after multimodality therapy including surgery for metastatic esophageal cancer. Acta Chir Belg 2018; 118: 227-232.
Mohnike K, Neumann K, Hass P et al. Radioablation of adrenal gland malignomas with interstitial high-dose-rate brachytherapy: Efficacy and outcome. Strahlenther Onkol 2017; 193: 612-619.
Matsui Y, Hiraki T, Gobara H et al. Percutaneous radiofrequency ablation for pulmonary metastases from esophageal cancer: retrospective evaluation of 21 patients. J Vasc Interv Radiol 2014; 25: 1566-1572.
Baba Y, Watanabe M, Kawanaka K et al. Radiofrequency ablation for pulmonary metastases from esophageal squamous cell carcinoma. Dis Esophagus 2014; 27: 36-41.
Mohnike K, Wieners G, Schwartz F et al. Computed tomography-guided high-dose-rate brachytherapy in hepatocellular carcinoma: safety, efficacy, and effect on survival. Int J Radiat Oncol Biol Phys 2010; 78: 172-179.
Katano A, Yamashita H, Nakagawa K. Stereotactic body radiotherapy for oligo-recurrence in the liver in a patient with esophageal carcinoma: A case report. Mol Clin Oncol 2017; 7: 1061-1063.
Egawa T, Okubo Y, Kemmochi T et al. A case of liver metastasis from esophageal cancer treated with stereotactic body radiation therapy. Gan To Kagaku Ryoho 2013; 40: 1850-1852.
Milano MT, Katz AW, Zhang H et al. Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study. Int J Radiat Oncol Biol Phys 2012; 83: 878-886.
Yeung R, Hamm J, Liu M, Schellenberg D. Institutional analysis of stereotactic body radiotherapy (SBRT) for oligometastatic lymph node metastases. Radiat Oncol 2017; 12: 105.
Quick links
© 2018 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe